Chemo-radiotherapy for advanced non-small cell lung cancer: Concurrent or sequential? It's no longer the question: A systematic review

International Journal of Cancer

Volumn 127, Issue 3, 2010, Pages 718-728

  Liang, Hui Ying ^a,b   Zhou, Hao ^c   Li, Xue An ^a,b   Yin, Zhi Hua ^a,b   Guan, Peng ^a,b   Zhou, Bao Sen ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b University of Liaoning Province   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Advanced NSCLC; Concurrent chemo radiotherapy; Sequential chemoradiotherapy; Systematic review

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL DECISION MAKING; CLINICAL TRIAL; ESOPHAGITIS; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SENSITIVITY ANALYSIS; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77954430677     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25087     Document Type: Article

References (55)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. vol. 1.0. Lyon, France: IARC Press, 2001.
3. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996-3018.
4. Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R, Dunant A, Torri V, Rosell R, Seymour L, Spiro S, Rolland E, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-59.
5. Ulutin H, Aksu G. Radiotherapy and surgery in the management of non-small cell lung cancer in the elderly patients, a review of the recent literature. Cancer Therapy 2005;3:95-100.
6. Azim H-A, Elattar I, Loberiza F, Azim H, Mok T, Ganti A. Third generation triplet cytotoxic chemotherapy in advanced nonsmall cell lung cancer: A systematic overview. Lung Cancer 2009;64:194-98.
7. Vokes E, Crawford J, Bogart J, Socinski M, Clamon G, Green M. Concurrent Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer. Clinical Cancer Research 2005;11:5045s-50s.
8. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-17.
9. Bahl A, Sharma D, Julka P, Rath G. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. JCRT 2006;2:14-16. (Pubitemid 43253997)
10. Pritchard R, Anthony S. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer, A meta-analysis. Ann Intern Med 1996;125:723-29. (Pubitemid 126450359)
11. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
12. Sirzén F, Kjellén E, Sörenson S, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003;42:493-515.
13. Pignon J, Stewart L. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer 1996;77:2413-14.
14. Sörenson S, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 2001;40:327-39.
15. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-99.
16. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Sause W, Cox JD. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:(abstr 2499).
17. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
18. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-21.
19. Fournel P, Robinet G, Thomas P, Souquet P, Léna H, Vergnenégre A, Delhoume J, Le-Treut J, Silvani J, Dansin E, Bozonnat M, Daurés J, et al. Randomized phase III trial of sequential chemo-radiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-17.
20. Clamon G, Herndon J, Cooper R, Chang A, Rosenman J, Green M. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11. (Pubitemid 29022371)
21. Dasgupta A, Dasgupta C, Basu S, Majumdar A. A prospective and randomized study of radiotherapy, sequential chemotherapy radiotherapy and concomitant chemotherapy-radiotherapy in unresectable non small cell carcinoma of the lung. J Cancer Res Ther 2006;2:47-51. (Pubitemid 43926440)
22. Ulutin H, Güden M, Oysul K, Sürenkök S, Pak Y. Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. Radiat Med 2000;18:93-96. (Pubitemid 30321210)
23. Scagliotti G, Szczesna A, Ramlau R, Cardenal F, Mattson K, Van-Zandwijk N, Price A, Lebeau B, Debus J, Manegold C. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer 2006;94:1375-82.
24. Liddle J, Williamson M, Irwig L. Method for Evaluating Research and Guideline Evidence. Sydney, Australia: NSW Health Department, 1996.
25. Simes R. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987;6:11-29. (Pubitemid 17017356)
26. Stouffer SA, Suchman EA, DeVinney LC, Star SA, Williams RM. The American Soldier: Adjustment During Army Life. vol. 1. Princeton, NJ: Princeton University Press, 1949.
27. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-59.
28. Colditz G, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 1995;142:371-82.
29. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
30. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-14.
31. Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
32. Egger M, Smith G, Schneider M, C M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
33. Bradburn M, Deeks J, Altman D. Metan-an alternative meta-analysis command. In Stata Technical Bulletin, Vol. 8. Stata Corporation 1999.
34. Saha S, Das Gupta P, Gangopadhaya S. Various chemoradiation modalities in inoperable non-small-cell lung cancer: an Indian experience. Lung Cancer 2004;45:S54-55.
35. Willner J, Huber R, Poellinger B, Gosse H, Friedrich A, Mose S, Schmidt M, Flentje M. CTRT 99/97 a randomized trial of simultaneous paclitaxel and radiotherapy vs. radiotherapy alone following induction chemotherapy in stage III inoperable NSCLC. Int J Radiat Oncol Biol Phys 2003;57:S140.
36. Pierre F, Maurice P, Gilles R, Pascal T, Pierre-Jean S, Herve L. A randomized phase III trial of sequential chemoradiotherapy in locally advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:(abstr 312).
37. Huber R, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K. Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006;24:4397-404.
38. Belani C, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran-WJ J. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-91.
39. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response,toxicity,failure patterns,and survival in five Radiation Therapy Oncology Group (RTOG)trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int.J.Radiat.Oncol.Biol.Phys. 1998;42:469-78.
40. Tada T, Minakuchi K, Matsui K, Kin H, Nishiguchi T, Fukuda H. A single institutional subset analysis of the WJLCG study comparing concurrent and sequential chemoradiotherapy for stage III non-small-cell lung cancer. Radiat Med 2004;22:163-67. (Pubitemid 38980994)
41. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60.
42. Vergnenegre A, Combescure C, Fournel P, Bayle S, Gimenez C, Souquet P, Lena H, Perol M, Delhoume J. Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01). Ann Oncol 2006;17:1269-74.
43. Gagel B, Piroth M, Pinkawa M, Reinartz P, Krohn T, Kaiser H, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble M. Sequential (gemcitabine/ vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. BMC Cancer 2007;7:112.
44. Jiang X, Song D, Zhang W, Wu J. Clinical study on concurrent and sequential therapy of intensity modulated radiation therapy(IMRT)combined with NP regimen chemotherapy in the treatment of middle and advanced non-small cell lung cancer. Chinese-German Journal of Clinical Oncology 2007;6:2-4.
45. Uitterhoeve A, Koolen M, Os R, Koedooder K, Kar M, Pieters B, Koning C. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. Radiat Oncol 2007;2:27.
46. Dillman R, Herndon J, Seagren S, Eaton W, Green M. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-15. (Pubitemid 26302034)
47. Le-Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier M, Douillard J, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
48. Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Dar A, Turrisi A. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64.
49. Rosenthal D, Pistenmaa D, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys 1994;28:315-20. (Pubitemid 24012886)
50. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
51. Sculier J, Moro-Sibilot D. First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009;33:915-30.
52. Socinski M, Rosenman J, Halle J, Schell M, Lin Y, Russo S, Rivera M, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck F. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-23.
53. El-Sharouni S, Kal H, Battermann J, Schramel F. Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer. Anticancer Res 2006;26:495-505. (Pubitemid 43206007)
54. Clarke M, Stewart L. Obtaining individual patient data from randomised controlled trials. In: Egger M, Smith G, Altman D. (eds) Systemic Reviews in Health Care Meta-analysis in Contexted. London: BMJ, 2001.
55. Zelen M. Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors. J Clin Oncol 1983;1:164-69.